Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia

Fig. 1

a Diagram showing the principal of microarray-based analysis. b OS according to high gene expression (genehigh, red) and low gene expression (genelow, blue), analyzed using microarray datasets GSE12417 and GSE8970. GSE12417 had two independent cohorts, examined by two microarray plateforms GPL570 and GPL96. c OS according to UBE2E1 high (red) and UBE2E1 low (blue) in validation cohort. d Relative UBE2E1 expression in patients with different performance status. e Relative UBE2E1 expression in patients with different responses to induction chemotherapy, no response (NR) vs. complete response (CR). (*p < 0.05, **p < 0.01)

Back to article page